Sagimet Biosciences (NASDAQ:SGMT) vs. Valneva (NASDAQ:VALN) Head to Head Analysis

Sagimet Biosciences (NASDAQ:SGMT) and Valneva (NASDAQ:VALN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, analyst recommendations, dividends and profitability.

Volatility & Risk

Sagimet Biosciences has a beta of 3.45, suggesting that its share price is 245% more volatile than the S&P 500. Comparatively, Valneva has a beta of 1.67, suggesting that its share price is 67% more volatile than the S&P 500.

Profitability

This table compares Sagimet Biosciences and Valneva’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sagimet Biosciences	N/A	-31.96%	-30.57%
Valneva	-110.33%	-153.20%	-39.50%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Sagimet Biosciences and Valneva, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sagimet Biosciences	1	2	7	0	2.60
Valneva	2	0	2	0	2.00

Sagimet Biosciences currently has a consensus target price of $29.17, indicating a potential upside of 167.09%. Valneva has a consensus target price of $9.30, indicating a potential upside of 31.73%. Given Sagimet Biosciences’ stronger consensus rating and higher possible upside, equities analysts clearly believe Sagimet Biosciences is more favorable than Valneva.

Earnings and Valuation

This table compares Sagimet Biosciences and Valneva”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sagimet Biosciences	$2.00 million	339.39	-$51.04 million	($1.28)	-8.53
Valneva	$197.56 million	3.39	-$130.33 million	($2.11)	-3.35

Sagimet Biosciences has higher earnings, but lower revenue than Valneva. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

87.9% of Sagimet Biosciences shares are owned by institutional investors. Comparatively, 11.4% of Valneva shares are owned by institutional investors. 11.5% of Sagimet Biosciences shares are owned by insiders. Comparatively, 14.9% of Valneva shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Sagimet Biosciences beats Valneva on 11 of the 14 factors compared between the two stocks.

About Sagimet Biosciences

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company’s lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.